Trending Topic

abstract blue eye
8 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

On 28 May 2024, enrolment in phase III clinical trials for sozinibercept in neovascular age-related macular degeneration (nAMD) was completed.1 These trials include two large multicentre, double-masked, randomized controlled trials (RCTs): COAST (OPT-302 with aflibercept in neovascular age-related macular degeneration; ClinicalTrials.gov identifier: NCT04757636) and ShORe (OPT-302 with ranibizumab in neovascular age-related macular degeneration; ClinicalTrials.gov identifier: NCT04757610).2,3 These trials represent one of the largest phase […]

Carlos Pavesio, EURETINA 2021: Fluocinolone Acetonide Insert for Noninfectious Uveitis

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: Nov 26th 2021

It was great to speak with Carlos Pavesio (Moorfields Eye Hospital, London, UK) about unmet needs in treatment of noninfectious uveitis, and the clinical evidence supporting the efficacy of the fluocinolone acetonide insert.

 

Questions:

  1. What are the unmet needs in the treatment of noninfectious uveitis? (00:33)
  2. Could you tell us a little about the fluocinolone acetonide insert and the clinical evidence supporting its use in noninfectious uveitis? (02:13)

Speaker Disclosure: Carlos Pavesio has no financial or non-financial relationships or activities to declare in relation to this interview.

Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Lisa Glass.

Filmed in coverage of EURETINA 2021.

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Close Popup